organ transplant

ARPA-H has awarded up to $176.8 million to five teams building 3D-bioprinted kidneys and livers designed to work without immunosuppressive drugs, targeting first-in-human trials within five years.

Gene-edited pig kidneys have entered FDA-cleared clinical trials, a $176.8 million federal program is funding five teams to bioprint livers, and new cryopreservation methods could extend organ viability from hours to days.